Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab versus prednisone added to csDMARDs in rheumatoid arthritis
NL-OMON56342Phase 4Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tocilizumab and prednisone in rheumatoid arthritis (RA) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Change in CDAI from baseline to 6, 9, and 12 months. Started Feb 2020; status: completed.
02
Drugs
tocilizumabprednisone
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON56342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56342.